Rapporto ISS COVID-19 n. 14/2020 English version - Interim guidance for the appropriate support of people with enzymopenia G6PD (favism) in the current SARS-CoV-2 emergency scenario. Version April 14, 2020
Rapporti ISS COVID-19 in English
Istituto Superiore di Sanità
Interim guidance for the appropriate support of people with enzymopenia G6PD (favism) in the current SARS-CoV-2 emergency scenario. Version April 14, 2020.
ISS COVID-19 Rare Diseases Working Group
2020, 9 p. Rapporto ISS COVID-19 n. 14/2020 – English version
This report provides interim indications for appropriate support to people with deficiency of G6PD enzyme (favism) in the current SARS-CoV-2 emergency scenario. The G6PD deficiency is an endemic condition in our Country and people with this deficit are almost always asymptomatic, however some factors inducing oxidative stress on red blood cells can trigger hemolytic crises. The onset and intensity of the hemolytic crisis depends on the dose of the triggering agent. These agents include drugs such as chloroquine and hydroxychloroquine, authorized by AIFA (Italian Medicines Agency) and used in patients to deal with the SARS-CoV-2 coronavirus pandemic in the absence of proven effective treatment. In order to ensure correct management of the SARS-CoV-2 patient, it is necessary to characterize his G6PD status before starting the pharmacological treatment with chloroquine or hydroxychloroquine, through the medical history or by the screening or quantitative test of G6PD activity. Therefore, it is necessary to give adequate attention to the warning on the use of chloroquine and hydroxychloroquine in the presence of the enzyme G6PD deficiency.
Pubblicato il 24/04/2020